Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 17/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692011 | 0.87 | TRPM8 (0.67) | TRPM8 | |
| SCHEMBL2731319 | 0.87 | TRPM8 (0.67) | TRPM8 | |
| SCHEMBL30582854 | 0.87 | TRPM8 (0.70) | TRPM8 | |
| SCHEMBL2730206 | 0.87 | TRPM8 (0.70) | TRPM8 | |
| SCHEMBL2730817 | 0.84 | TRPM8 (0.70) | TRPM8 | |
| SCHEMBL18199129 | 0.84 | TRPM8 (0.71) | TRPM8 | |
| SCHEMBL30582851 | 0.84 | TRPM8 (0.71) | TRPM8 | |
| SCHEMBL30582869 | 0.84 | TRPM8 (0.70) | TRPM8 | |
| SCHEMBL6400864 | 0.84 | TRPM8 (0.74) | TRPM8CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL30582823 | 0.83 | TRPM8 (0.83) | TRPM8CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234450-B2 | Preparations having a cooling effect | SYMRISE AG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-10953007-B2 | Compounds useful as modulators of TRPM8 | FIRMENICH INCORPORATED (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3470407-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10016418-B2 | Compounds useful as modulators of TRPM8 | Seaomyx, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10016418-B2 | Compounds useful as modulators of TRPM8 | Seaomyx, Inc. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180055069-A1 | PREPARATIONS | SYMRISE AG (DE) | 2018-03-01 | — | — | US | disclosed |
| US-20180055069-A1 | PREPARATIONS | SYMRISE AG (DE) | 2018-03-01 | — | — | US | disclosed |
| US-20180049449-A1 | PREPARATIONS | SYMRISE AG (DE) | 2018-02-22 | — | — | US | disclosed |
| US-20180049449-A1 | PREPARATIONS | SYMRISE AG (DE) | 2018-02-22 | — | — | US | disclosed |
| US-20160317532-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2016-11-03 | — | — | US | disclosed |
| US-20160317532-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED | 2016-11-03 | — | — | US | disclosed |
| US-9394287-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9394287-B2 | Compounds useful as modulators of TRPM8 | SENOMYX, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150313820-A1 | PREPARATIONS | SYMRISE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| US-20150313820-A1 | PREPARATIONS | SYMRISE AG (DE) | 2015-11-05 | — | — | US | disclosed |
| WO-2012061698-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012061698-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953007-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPM6 | TRPM8 1/4885NPC1 1050/4885RAB9A 1469/4885 |
| US-11234450-B2 | Preparations having a cooling effect | CRAT, CPT2, CPT1A | TRPM8 60/4885NPC1 1221/4885RAB9A 3995/4885 |
| US-10016418-B2 | Compounds useful as modulators of TRPM8 | TRPM8, TRPM7, TRPM6 | TRPM8 1/4885NPC1 1050/4885RAB9A 1469/4885 |
| US-20160317532-A1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | TRPM8, TRPM7, TRPM6 | TRPM8 1/4885NPC1 1050/4885RAB9A 1469/4885 |
| US-20180049449-A1 | PREPARATIONS | CRAT, ACAT2, TAS2R50 | TRPM8 101/4885NPC1 2008/4885RAB9A 3798/4885 |
| US-20180055069-A1 | PREPARATIONS | CRAT, ACAT2, TAS2R50 | TRPM8 101/4885NPC1 2008/4885RAB9A 3798/4885 |
| US-20150313820-A1 | PREPARATIONS | CRAT, ACAT2, TAS2R50 | TRPM8 101/4885NPC1 2008/4885RAB9A 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.